US senator Hatch warns about too little exclusivity in biosimilars bill
This article was originally published in Scrip
Executive Summary
Venture capital funding for biotechnology firms will dry up and innovator companies will move jobs outside of the US if a biosimilars measure with insufficient data exclusivity protection passes Congress, US senator Orrin Hatch said.